1. Scrip
  2. >>Business

Indivior Reorganizing And Re-Investing In US Commercial Functions

Workforce Cuts Expected

 
• By John Davis

Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.  

Business
• Source: Shutterstock

The US-headquartered but UK-listed Indivior plc has announced an undisclosed number of job cuts and a restructuring of some its US commercial operations to reduce costs, support its marketed Sublocade (buprenorphine extended-release) injection, and back its early R&D pipeline.

The changes are being made in response to this year’s COVID-19 pandemic, Indivior explained. At the end of July, the company reported a $145m loss on a reported basis in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list